PR

ProGen, Co,, LTD.

Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.

296160 | KO

Overview

Corporate Details

ISIN(s):
KR7296160005
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172, 6층, 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ProGen is a clinical-stage biotechnology company focused on the research and development of innovative therapeutics. The company specializes in creating protein-based immunotherapies through its proprietary Neo Tri-ImmunoGlobulin (NTIG) platform, a next-generation technology for developing multi-specific fusion proteins and antibody treatments. ProGen's pipeline primarily targets metabolic diseases, immune disorders, and cancer. The company's business model is centered on platform-based drug discovery and pursuing global partnerships for late-stage clinical development and commercialization of its long-acting biologics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.8 KB
2025-08-18 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 24.2 KB
2025-08-18 00:00
Regulatory News Service
지정자문인선임계약의변경
Korean 5.1 KB
2025-07-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-07-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 99.0 KB
2025-07-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 122.5 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-11 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.7 KB
2025-06-11 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 42.2 KB
2025-06-11 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.8 KB
2025-05-28 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 43.5 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 123.5 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB

Automate Your Workflow. Get a real-time feed of all ProGen, Co,, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProGen, Co,, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProGen, Co,, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America
APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060

Talk to a Data Expert

Have a question? We'll get back to you promptly.